Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 273-282-8 | CAS number: 68955-56-6
Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- repeated dose toxicity: inhalation
- Data waiving:
- exposure considerations
- Justification for data waiving:
- other:
Data source
Materials and methods
Results and discussion
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Executive summary:
Waiving: Additional testing of C36-alkylenediamine (Dimerdiamine) for inhalation toxicity is not appropriate, as exposure of humans via inhalation is not likely. Due to the very low vapour pressure (2.2 x10-5 hPa @ 20°C) inhalation of vapours leading to irritation of airways will not occur. Also aerosol exposures are not likely to occur in view of its only use as industrial intermediate under conditions that do not lead to aerosol formation. Testing for toxicity by inhalation route is therefore generally not needed according to REACH regulation (EC) 1907/2006 (Annex IX, point 8.6.2, column 2).
Furthermore, testing would also not be justified because of animal welfare reasons. C36-alkylenediamine is severely irritating / corrosive to skin and is classified as corrosive to the eyes, whereas its systemic toxicity is low. Due the very low vp (2.2 x10-7 Pa @ 20°C) and viscosity of substance, inhalation exposures would only be possible in the form of aerosol, consisting of larger droplets depositing in upper airways. It can be expected that aerosol levels which would lead to severe local damage in the airways will not lead to systemic toxicity following absorption from larger and smaller bronchi, as most of the inhaled amounts will deposit in larger airways and will be ingested after mucociliary transport to the pharynx.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
